Carboplatin dosing in obese women with ovarian cancer

Body mass index impacts ovarian cancer chemotherapy dosages

Approximately 30 percent of those women studied were obese (BMI of 30 or greater) and 31 percent were overweight (BMI between 25 and 29); fewer ...

Dosing of chemotherapy in obese and cachectic patients - OUCI

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol. 2009;64(1):115–22. https://doi.

For Best Survival in Ovarian Cancer, Chemotherapy Doses Must be ...

Approximately 30 percent of participants were obese (BMI [body mass index] of 30 or more), and 31 percent were overweight (BMI of 25-29); fewer ...

Computed Tomography–Based Body Composition in Patients With ...

Although their evaluation was dedicated to the overweight/obese group (n=48), patients who experienced dose-limiting toxicity had lower BMI and lower fat mass ...

Conditioning Chemotherapy Dose Adjustment in Obese Patients

Compared underweight (BMI <. 18), normal (18-25), overweight (>25-30), obese. (>30-34), and morbidly obese ( 35). Median follow-up of 51 to 87 mo. Dosing: Basis ...

Obesity and chemotherapy administration: between empiric and ...

The worldwide prevalence of obesity has nearly doubled between 1980 and 2008. In 2008, 10% of men and 14% of women in the world were obese (BMI ...

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian ...

A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of drug delivery) plus carboplatin every 3 weeks or the ...

Association of body composition with toxicity to first-line ...

Authors observed that, among overweight and obese patients, those who discontinued chemotherapy or reduced the dose due to the presence of adverse events grade ...

Obesity and Ovarian Cancer Survival: A Systematic Review and ...

Inclusion of underweight women (who are likely to have worse outcomes) in the reference group and/or overweight women in the obese group may underestimate the ...

What is the impact of dose modification in adjuvant chemotherapy ...

... BMI, RDI and patient outcomes. More patients in the obese group received under-dosing of carboplatin compared to the normal and over-weight ...

Carboplatin Injection

Carboplatin Injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 IV on day 1 every ...

Obesity and survival among women with ovarian cancer - Nature

However, in the overweight and morbidly obese groups there was significant heterogeneity between the studies (all P<0.05). Using BMI as a ...

Adjustment of creatinine clearance for carboplatin dosing in ...

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J ...

158 Obesity and carboplatin dosing in gynecologic oncology patients

158 Obesity and carboplatin dosing in gynecologic oncology patients ... obese compared to non-obese patients. No difference in progression ...

Dosing of chemotherapy in obese and cachectic patients

Sections 3 and 4 asked for the following issues in obese and cachectic patients respectively: use of BMI to determine obesity or cachexia, BMI ...

Impact of Body Mass Index (BMI) on Chemotherapy-associated

Patients were divided into four groups according to BMI: (1) underweight - BMI <20, (2) normal weight – BMI=20-25, (3) overweight - BMI >25-30 and (4) obese - ...

Inpharma 1648 - 26 Jul 2008 1

by BMI, but there was a trend towards increased risk of progression among obese women. Wright JD, et al. Carboplatin dosing in obese women with ovarian cancer: ...

Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer

... Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother. Pharmacol. 2009, 64, 115–122. [Google ...

Presenting Author(s) - HOPA 2024

Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2008;109(3):353-358. doi:10.1016/j.ygyno.2008.02 ...

Back to the future: Chemotherapy dosing in overweight and obese ...

... BMI, but it appeared strongest in healthy-weight women. They also observed that obese patients with ovarian cancer receiving full-dose ...